Journal of Cancer 2018, Vol. 9
129
Ivyspring
Journal of Cancer
International Publisher
2018; 9(1): 129-134. doi: 10.7150/jca.21842
Research Paper
Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells Shaohua Cui, Lili Dong, Jialin Qian, Lin Ye, Liyan Jiang Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University Corresponding author: Liyan Jiang, Department of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241# HuaiHai (W.) Rd, Shanghai, 200030, China. Tel: +86 13916146759 Fax: +86 021-32260856 E-mail:
[email protected] © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Received: 2017.07.10; Accepted: 2017.10.06; Published: 2018.01.01
Abstract Purpose: To explore the possible correlation between programmed death ligand 1 (PD-L1)/tumor-infiltrating lymphocytes (TIL) status and clinical factors in non-small cell lung (NSCLC). Materials and Methods: A total of 126 surgical NSCLC samples with stage I to IIIA were retrospectively collected and analyzed. Immunohistochemistry (IHC) assays were used to detect PD-L1 protein expression. PD-L1 positivity on tumor cells was defined by positive tumor cell (TC) percentage using 5% cutoff value. Results: Thirty-seven patients (29.4%), thirty patients (23.8%), six patients (4.8%) and fifty-three patients (42%) were classified as type I (PD-L1+, TIL+), type II (PD-L1-, TIL-), type III (PD-L1+, TIL-) and type IV (PD-L1-, TIL+) tumor environments according to PD-L1/TIL status, respectively. Statistical differences could be observed in factors including gender (P
